Keyword Analysis & Research: listedness

Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
listedness0.80.536029610

Keyword Research: People who searched listedness also searched

Keyword CPC PCC Volume Score
listedness1.680.5135183
listedness in pharmacovigilance1.960.3195257
listedness meaning1.830.8665430
listedness and expectedness0.950.7612922
listedness assessment in pharmacovigilance1.961893892
listedness definition0.640.7815732

Search Results related to listedness on Search Engine

  • 18. i. Listedness/Expectedness assessment – Introduction

    allaboutpharmacovigilance.org

    https://allaboutpharmacovigilance.org/18-i-listedness-expectedness-assessment-introduction/

    WEBAug 28, 2019 · Listedness/Expectedness assessment – Introduction | Pharmacovigilance. There are two principal criteria that control the priority for documenting, validating, evaluating and regulatory-reporting of ADR cases: seriousness and expectedness. The concept of expectedness refers to events that may or may not have previously been observed and ...

    DA: 100 PA: 88 MOZ Rank: 89

  • Listedness, Labelling or Expectedness assessment in …

    publicsafetyandvigilance.com

    https://publicsafetyandvigilance.com/2020/09/assessing-labelling-listedness-expectedness-in-pharmacovigilance-differences-methodology-used-in-assessment/

    WEBSep 6, 2020 Public Safety & Vigilance Aggregate report writing, Individual Case Safety Reports, Pharmacovigilance Expectedness, Labelling assessment, Listedness, Pharmacovigilance This concept involves determining whether any adverse drug reaction or adverse drug event is already known/already documented/already observed in subjects/patients ...

    DA: 61 PA: 21 MOZ Rank: 90

  • 18.iii. LISTEDNESS/ EXPECTEDNESS ASSESSMENT – Guidelines and Examples

    allaboutpharmacovigilance.org

    https://allaboutpharmacovigilance.org/19-1-guidelines-and-examples-of-expectedness-assessment/

    WEBAug 31, 2019 · LISTEDNESS/ EXPECTEDNESS ASSESSMENT – Guidelines and Examples | Pharmacovigilance. The determination of whether an ADR is or is not expected is not an exact science; there are many grey areas. A decision in many instances will have to be based on clinical evaluation of inadequate case information.

    DA: 5 PA: 24 MOZ Rank: 13

  • 18.ii. LISTEDNESS/ EXPECTEDNESS ASSESSMENT – Reference safety

    allaboutpharmacovigilance.org

    https://allaboutpharmacovigilance.org/18-ii-listedness-expectedness-assessment-reference-safety-information-documents/

    WEBAug 31, 2019 · LISTEDNESS/ EXPECTEDNESS ASSESSMENT – Reference safety information documents | Pharmacovigilance. As per regulatory authorities an adverse reaction will be unexpected unless it is mentioned in the appropriate reference safety information (RSI) document (s) for the drug. The purpose of RSI is, of course, not limited to the determination of ...

    DA: 61 PA: 1 MOZ Rank: 10

  • Guideline on good pharmacovigilance practices (GVP)

    europa.eu

    https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-and-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf

    WEBGuideline on good pharmacovigilance practices (GVP) ... Agency

    DA: 46 PA: 74 MOZ Rank: 37

  • MedDRA in pharmacovigilance industry perspective

    meddra.org

    https://admin.meddra.org/sites/default/files/page/documents_insert/christina_winter_3_meddra_in_pharmacovigilance_industry_perspective_.pdf

    WEBAutomated listedness • Listedness* may be assessed inconsistently in a large organisation o Example: if headache is labelled, is migraine listed? • For consistency, some companies maintain a set of MedDRA terms that are considered listed for each undesirable effect in the core safety information

    DA: 27 PA: 9 MOZ Rank: 43

  • Guideline on good pharmacovigilance practices (GVP)

    europa.eu

    https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-vi-management-and-reporting-adverse-reactions-medicinal-products-superseded_en.pdf

    WEB22 June 2012 . EMA/873138/2011 (superseded version) Guideline on good pharmacovigilance practices (GVP) Module VI – Management and reporting of adverse reactions to medicinal

    DA: 49 PA: 83 MOZ Rank: 61

  • Assessing Labelling, Listedness, Expectedness in …

    linkedin.com

    https://www.linkedin.com/pulse/assessing-labelling-listedness-expectedness-used-and-vigilance

    WEBSep 7, 2020 · Assessing Labelling, Listedness, Expectedness in Pharmacovigilance: Differences & Methodology used in assessment. Xpert PV. Public Safety & Vigilance. Published Sep 7, 2020. + Follow.

    DA: 44 PA: 73 MOZ Rank: 93

  • WHO PHARMACOVIGILANCE INDICATORS: A …

    who.int

    https://apps.who.int/iris/bitstream/handle/10665/186642/9789241508254_eng.pdf

    WEBvii How to use this manual This manual provides a practical method for determining the pharmaco-vigilance indices. It is designed to be simple and can be understood by any

    DA: 46 PA: 80 MOZ Rank: 78

  • The use of the WHO-UMC system for standardised case …

    who.int

    https://www.who.int/docs/default-source/medicines/pharmacovigilance/whocausality-assessment.pdf

    WEBThe various causality categories are listed in Table 2. The original descriptions and an explanation are presented under ‘Definitions’ (3). In Table 2 the assessment criteria of the various categories are shown in a point-wise way, as has been developed for practical training during the UMC Training Courses. Table 2. WHO-UMC Causality ...

    DA: 17 PA: 18 MOZ Rank: 62